Join the 200th Anniversary Celebration

Original Article

Brief Report

Deficiency of a Dystrophin-Associated Glycoprotein (Adhalin) in a Patient with Muscular Dystrophy and Cardiomyopathy

Ricardo Fadic, M.D., Yoshihida Sunada, Ph.D., Andrew J. Waclawik, M.D., Scott Buck, M.D., Paul J. Lewandoski, Kevin P. Campbell, Ph.D., and Barend P. Lotz, M.D.

N Engl J Med 1996; 334:362-366February 8, 1996

Article

Cardiac muscle is commonly affected in muscular dystrophies.1-4 X-linked Duchenne's muscular dystrophy and Becker's muscular dystrophy are caused by mutations in the gene encoding dystrophin,5,6 a membrane cytoskeletal protein.7 In skeletal and cardiac muscle, dystrophin is associated with a large oligomeric complex of sarcolemmal glycoproteins.8,9 This dystrophin–glycoprotein complex is composed of five glycoproteins (35, 43 doublet, 50, and 156 kd) and two proteins (25 and 59 kd). It spans the sarcolemma to provide linkage between the subsarcolemmal cytoskeleton and laminin, a major component of the extracellular matrix.9,10

In Duchenne's and Becker's muscular dystrophies, the primary deficiency in dystrophin is associated with a commensurate secondary reduction in the other dystrophin-associated proteins.11,12 Disruption of the linkage between the cytoskeleton of the muscle fiber and the extracellular matrix has also been proposed as a factor in three autosomal recessive inherited diseases. In Fukuyama-type congenital muscular dystrophy, recently mapped to chromosome 9q31–33,13 all the dystrophin-associated proteins, especially the 43-kd dystrophin-associated glycoprotein, have low expression.14 This disorder is associated with structural abnormalities in the brain.15

The second type is merosin-negative congenital muscular dystrophy, which has been linked to chromosome 6q2.16,17 Finally, severe childhood autosomal recessive muscular dystrophy has been attributed to a deficiency of the 50-kd dystrophin-associated glycoprotein.18 Severe childhood autosomal recessive muscular dystrophy is prevalent in North Africa, and its clinical presentation is similar to that of Duchenne's and Becker's muscular dystrophies except that both sexes are affected.19 The 50-kd dystrophin-associated glycoprotein was named “adhalin” from the Arabic adhal (muscle), and it has been linked in North African populations to an unidentified gene in the pericentromeric region of chromosome 13q.20 Adhalin deficiency has also been reported in Europe,21 Brazil,22 Japan,23 and Pakistan.24 Interestingly, the adhalin gene has been mapped to chromosome 17q12–21.33,25,26 and missense mutations in the adhalin gene have been demonstrated.27 Cardiac abnormalities develop in patients with the disease,19 but the expression of the dystrophin-associated proteins, including adhalin, in cardiac muscle has not been determined.

We report here on a patient with muscular dystrophy and dilated cardiomyopathy related to adhalin deficiency in both skeletal and cardiac muscle.

Case Report

A 13-year-old boy who had previously been given a diagnosis of Becker's muscular dystrophy was referred to the University of Wisconsin Hospital and Clinics for evaluation of dilated cardiomyopathy and congestive heart failure. He was asymptomatic until nine years of age, when proximal muscle weakness developed. Examination at that time showed flexion contracture at the ankles, hypertrophy of the calf muscles, grade 4/5 strength (according to the criteria of the British Medical Research Council) in the hip flexors, and Gowers' sign. The serum creatine kinase level was 11,560 U per liter. There was no family history of consanguinity or neuromuscular disease. Both his sister and his mother had normal serum creatine kinase values.

The results of nerve-conduction studies were normal. Electromyographic examination revealed spontaneous activity and myopathic motor units in both arm and leg muscles. A biopsy of the biceps muscle demonstrated features of muscular dystrophy, including variation in fiber size, degenerating and regenerating fibers, and an increase in endomysial connective tissue. Analysis of dystrophin by Western blotting produced normal results. Clinically, the patient's muscle power continued to deteriorate slowly. A chest radiograph obtained at the age of 13 to evaluate symptoms of persistent cough showed global cardiomegaly. An electrocardiogram revealed sinus tachycardia with an RSR pattern in lead V1 and normal Q waves in leads I, aVL, V5, and V6. There were no tall right precordial R waves. Echocardiography demonstrated enlargement of all cardiac chambers and a decreased left ventricular ejection fraction (22 percent).

Examination showed atrophy in the upper portions of the trapezius, the latissimus dorsi, the sternal and pectoral portions of the pectoralis major, and the distal vastus lateralis muscles. There was hypertrophy of the gastrocnemius, extensor digitorum brevis, and adductor hallucis muscles. The patient had 4/5 strength in the deltoids, biceps, wrist flexors, hip flexors and adductors, and foot dorsiflexors and evertors on both sides of the body. There was mild winging of the scapulae. During the next three weeks, his congestive heart failure became refractory to diuretic therapy and to inotropic therapy with dopamine, dobutamine, and milrinone. He required a left ventricular assist device for circulatory support for six weeks and then underwent successful orthotopic heart transplantation.

Methods

Muscle-Biopsy Specimens

After informed consent had been obtained, a biopsy of the vastus lateralis muscle was performed with the patient under local anesthesia. All studies were reviewed and approved by the institutional review board. At the time of cardiac transplantation, a sample of the left ventricle was obtained. The specimens were snap-frozen first in isopentane chilled to -150°C and later in liquid nitrogen, and were stored at -80°C. Standard histologic and histochemical techniques were used to prepare 7-μm-thick frozen-muscle sections.26 Samples were also processed for electron microscopy according to standard methods.26 Muscles without histochemical abnormalities and muscles from patients with other muscular dystrophies were used as controls.

Antibodies

Monoclonal antibodies against the amino-terminus, carboxyl-terminus, and rod domain of dystrophin were obtained from Vector Laboratories (Burlingame, Calif.). A monoclonal antibody against adhalin (IVD31) had been previously characterized.28 Polyclonal antibodies against syntrophin triplet (59-kd dystrophin-associated protein), beta-dystroglycan (43-kd dystrophin-associated glycoprotein), and 35-kd dystrophin-associated glycoprotein were affinity-purified from sheep antiserum against purified dystroglycan as previously described.29

Indirect immunofluorescence microscopy of 7-μm-thick cryosections from skeletal- and heart-muscle specimens was performed as described previously.8,18,28-30 The sections were examined under a Zeiss axioplan fluorescence microscope (Berlin, Germany), and photographs were taken under identical conditions with the same exposure time.

Results

Light microscopical examination of the biopsy specimen of vastus lateralis muscle showed necrosis and regeneration of muscle fibers, some of which occurred in groups of fibers; increased endomysial fibrosis; splitting of muscle fibers; abnormal variation in muscle-fiber size; an increased number of muscle fibers containing internal nuclei; and an increased number of hypercontracted fibers. Many necrotic fibers were invaded by macrophages. The random distribution of histochemically defined fiber types was preserved. In cardiac muscle, there was an abnormal variation in the sizes of both muscle fibers and nuclei, increased endomysial fibrosis, and in many fibers, a marked increase in acid phosphatase and glycogen, especially in perinuclear vacuoles. There was no clear evidence of necrosis or regeneration of muscle fibers.

Electron microscopy showed breaks in the sarcolemma, with preserved basal laminae, in both skeletal and cardiac muscle (Figure 1AFigure 1Electron Micrographs of Skeletal Muscle (Panel A) and Cardiac Muscle (Panel B) from the Patient. and Figure 1B). In cardiac muscle, the most characteristic finding was the presence of autophagic vacuoles located in perinuclear regions, many of which contained glycogen particles. In skeletal muscle, there were ultrastructural changes corresponding to necrosis and regeneration of muscle fibers, including hypercontracted fibers. In muscle fibers with focal sarcolemmal defects, focal myofibrillar contractures were present adjacent to the breaks in some fibers.

The results of immunostaining in both skeletal and cardiac muscle showed normal reactivity for antibodies directed against the three portions of the dystrophin molecule (Figure 2Figure 2Skeletal and Cardiac Muscle from a Control and from the Patient Immunostained with Antibodies against Dystrophin, Adhalin, β-Dystroglycan, and 35-kd Dystrophin-Associated Glycoprotein (35-kd DAG).). Immunostaining of adhalin was drastically reduced in skeletal muscle, but a trace amount of adhalin was still present. However, in cardiac muscle, adhalin was undetectable by immunofluorescence. Immunostaining of the 35-kd dystrophin-associated glycoprotein was also significantly reduced in skeletal muscle and undetectable in cardiac muscle. It has been shown that adhalin deficiency causes a secondary reduction of 35-kd dystrophin-associated glycoprotein.18 Immunostaining of other components of the dystrophin–glycoprotein complex, including β-dystroglycan and syntrophin triplet, was normal in both skeletal and cardiac muscle.

Discussion

Adhalin is deficient in the skeletal muscle of patients with severe childhood autosomal recessive muscular dystrophy.18 This disease is relatively frequent in countries with a high rate of consanguinity.19 Cardiomegaly has been described in patients with the disease, but our patient is noteworthy because he had end-stage cardiomyopathy related to a deficiency of adhalin in the myocardium. The immunohistochemical findings in the skeletal and cardiac muscle from our patient are similar to those in cardiomyopathic hamsters, in which both cardiomyopathy and skeletal myopathy are related to adhalin deficiency.31 In our patient and in the animal model, inheritance is probably autosomal recessive.

Severe childhood autosomal recessive muscular dystrophy is phenotypically very similar to Duchenne's and Becker's muscular dystrophies, but it affects both males and females. It has a higher variability in the severity of the clinical course from one sibling to another, and symptoms suggestive of nervous system involvement have not been described.19 Becker's muscular dystrophy was originally diagnosed in our patient on the basis of his clinical presentation, creatine kinase levels, and skeletal-muscle pathological findings. However, as demonstrated in our patient, the diagnosis of a dystrophinopathy requires confirmation of dystrophin abnormalities by immunohistochemical means.

Several types of muscular dystrophy have been related to the disruption of different components of the link between the muscle cytoskeleton and the extracellular matrix.9,11-13,16,18 It has been postulated that the structurally weakened sarcolemma ruptures under mechanical stress, allowing uncontrolled ingress of extracellular-fluid components, particularly calcium, which triggers several processes that eventually result in necrosis of muscle fibers. This common pathophysiologic mechanism may explain the histologic similarities found among biopsy specimens of skeletal muscle from patients with congenital muscular dystrophies, dystrophinopathies, and severe childhood autosomal recessive muscular dystrophy. Degenerative changes in cardiac-muscle fibers and foci of fibrosis have been described both in dystrophinopathies1,32 and in Fukuyama-type congenital muscular dystrophy.33 The findings in our patient were similar. Why no necrotic fibers have been identified in cardiac muscle remains to be explained.

In dystrophinopathies, the cardiomyopathy appears to be unrelated to the course or severity of the skeletal myopathy. This observation is especially relevant to Becker's muscular dystrophy, in which severe myocardial involvement may be the presenting symptom.34-37 At the other end of the spectrum is X-linked cardiomyopathy, which is linked to the dystrophin gene but presents without clinical muscle weakness.38-40 The findings in some patients with X-linked cardiomyopathy suggest that deletions around exon 1 of the dystrophin gene may severely damage the function or expression of dystrophin in cardiac but not in skeletal muscle.39,40 The differences in skeletal- and cardiac-muscle involvement in patients with dystrophinopathies may be explained by different underlying mutations. Interestingly, Michels et al.41 did not find the common dystrophin-gene defect in 51 patients with idiopathic dilated cardiomyopathy, either familial or nonfamilial.

In our patient, dilated cardiomyopathy was related to adhalin deficiency. One might speculate that a defect in any of the dystrophin-associated proteins may present as a cardiomyopathy. Adhalin deficiency presents as an autosomal recessive condition,19 and only sporadic cases have been reported in countries with a low consanguinity rate. It is also genetically heterogeneous, since the defective gene was mapped to the pericentromeric region of chromosome 13q20 in the North African series, whereas the adhalin gene has been mapped to chromosome 17q12–21.33.25,26 Conversely, Fukuyama-type congenital muscular dystrophy has been mapped to chromosome 9q31–33,13 and merosin-negative congenital muscular dystrophy to chromosome 6q2.17 A missense mutation in the adhalin gene may be the cause of adhalin deficiency in some families,26,27 but different mechanisms are probably involved, since the linkage studies of the North African families indicate a locus on chromosome 13q.

Because dystrophinopathies and adhalin deficiency may be indistinguishable in terms of clinical presentation and pathological features of muscle, the diagnosis of Duchenne's or Becker's muscular dystrophy should be based on histochemically determined abnormalities of dystrophin. We propose that constituents of the dystrophin–glycoprotein complex and merosin be analyzed in all patients with the histologic findings suggestive of a dystrophinopathy and with normal results of muscle dystrophin analysis. Analysis of the dystrophin–glycoprotein complex should also be considered in patients with sporadic or familial non–X-linked dilated cardiomyopathy.

Supported in part by a grant from the Muscular Dystrophy Association. Dr. Campbell is an Investigator of the Howard Hughes Institute.

We are indebted to Masami Sunada and Sia Nizamuddin for expert technical assistance, and to Jo Ann Zaborowski for assistance in preparing the manuscript.

Source Information

From the Departments of Neurology (R.F., A.J.W., P.J.L., B.P.L.) and Pediatrics (S.B.), University of Wisconsin, Madison, and the Howard Hughes Medical Institute and the Department of Physiology and Biophysics, University of Iowa College of Medicine, Iowa City (Y.S., K.P.C.).

Address reprint requests to Dr. Lotz at the Department of Neurology, University of Wisconsin Hospital and Clinics, 600 Highland Ave., Madison, WI 53792.

References

References

  1. 1

    Farah MG, Evans EB, Vignos PJ Jr. Echocardiographic evaluation of left ventricular function in Duchenne's muscular dystrophy. Am J Med 1980;69:248-254
    CrossRef | Web of Science | Medline

  2. 2

    D'Orsogna L, O'Shea JP, Miller G. Cardiomyopathy of Duchenne muscular dystrophy. Pediatr Cardiol 1988;9:205-213
    CrossRef | Web of Science | Medline

  3. 3

    Vrints C, Mercelis R, Vanagt E, Snoeck J, Martin JJ. Cardiac manifestations of Becker-type muscular dystrophy. Acta Cardiol 1983;38:479-486
    Web of Science | Medline

  4. 4

    de Visser M, de Voogt WG, la Riviere GV. The heart in Becker muscular dystrophy, facioscapulohumeral dystrophy, and Bethlem myopathy. Muscle Nerve 1992;15:591-596
    CrossRef | Web of Science | Medline

  5. 5

    Hoffman EP, Brown RH Jr, Kunkel LM. Dystrophin: the protein product of the Duchenne muscular dystrophy locus. Cell 1987;51:919-928
    CrossRef | Web of Science | Medline

  6. 6

    Specht LA, Kunkel LM. Duchenne and Becker muscular dystrophies. In: Rosenberg RN, Prusiner SB, DiMauro S, Barchi RL, Kunkel LM, eds. The molecular and genetic basis of neurological disease. Boston: Butterworth–Heinemann, 1993:613-31.

  7. 7

    Koenig M, Monaco AP, Kunkel LM. The complete sequence of dystrophin predicts a rod-shaped cytoskeletal protein. Cell 1988;53:219-226
    CrossRef | Web of Science | Medline

  8. 8

    Ervasti JM, Campbell KP. Membrane organization of the dystrophin-glycoprotein complex. Cell 1991;66:1121-1131
    CrossRef | Web of Science | Medline

  9. 9

    Campbell KP. Three muscular dystrophies: loss of cytoskeleton-extracellular matrix linkage. Cell 1995;80:675-679
    CrossRef | Web of Science | Medline

  10. 10

    Ervasti JM, Campbell KP. A role for the dystrophin-glycoprotein complex as a transmembrane linker between laminin and actin. J Cell Biol 1993;122:809-823
    CrossRef | Web of Science | Medline

  11. 11

    Ohlendieck K, Matsumura K, Ionasescu VV, et al. Duchenne muscular dystrophy: deficiency of dystrophin-associated proteins in the sarcolemma. Neurology 1993;43:795-800
    Web of Science | Medline

  12. 12

    Matsumura K, Nonaka I, Tome FMS, et al. Mild deficiency of dystrophin-associated proteins in Becker muscular dystrophy patients having in-frame deletions in the rod domain of dystrophin. Am J Hum Genet 1993;53:409-416
    Web of Science | Medline

  13. 13

    Toda T, Segawa M, Nomura Y, et al. Localization of a gene for Fukuyama type congenital muscular dystrophy to chromosome 9q31-33. Nat Genet 1993;5:283-286[Erratum, Nat Genet 1994;7:113.]
    CrossRef | Web of Science | Medline

  14. 14

    Matsumura K, Nonaka I, Campbell KP. Abnormal expression of dystrophin-associated proteins in Fukuyama-type congenital muscular dystrophy. Lancet 1993;341:521-522
    CrossRef | Web of Science | Medline

  15. 15

    Fukuyama Y, Osawa M, Suzuki H. Congenital progressive muscular dystrophy of the Fukuyama type: clinical, genetic and pathological considerations. Brain Dev 1981;3:1-29
    Web of Science | Medline

  16. 16

    Tome FMS, Evangelista T, Leclerc A, et al. Congenital muscular dystrophy with merosin deficiency. C R Acad Sci III 1994;317:351-357
    Web of Science | Medline

  17. 17

    Hillaire D, Leclerc A, Faure S, et al. Localization of merosin-negative congenital muscular dystrophy to chromosome 6q2 by homozygosity mapping. Hum Mol Genet 1994;3:1657-1661
    CrossRef | Web of Science | Medline

  18. 18

    Matsumura K, Tome FMS, Collin H, et al. Deficiency of the 50K dystrophin-associated glycoprotein in severe childhood autosomal recessive muscular dystrophy. Nature 1992;359:320-322
    CrossRef | Web of Science | Medline

  19. 19

    Ben Hamida M, Fardeau M, Attia N. Severe childhood muscular dystrophy affecting both sexes and frequent in Tunisia. Muscle Nerve 1983;6:469-480
    CrossRef | Web of Science | Medline

  20. 20

    Azibi K, Bachner L, Beckmann JS, et al. Severe childhood autosomal recessive muscular dystrophy with the deficiency of the 50 kDa dystrophin-associated glycoprotein maps to chromosome 13q12. Hum Mol Genet 1993;2:1423-1428
    CrossRef | Web of Science | Medline

  21. 21

    Fardeau M, Matsumura K, Tome FMS, et al. Deficiency of the 50 kDa dystrophin associated glycoprotein (adhalin) in severe autosomal recessive muscular dystrophies in children native from European countries. C R Acad Sci III 1993;316:799-804
    Web of Science | Medline

  22. 22

    Zatz M, Matsumura K, Vainzof M, et al. Assessment of the 50-kDa dystrophin-associated glycoprotein in Brazilian patients with severe childhood autosomal recessive muscular dystrophy. J Neurol Sci 1994;123:122-128
    CrossRef | Web of Science | Medline

  23. 23

    Mizuno Y, Noguchi S, Yamamoto H, et al. Selective defect of sarcoglycan complex in severe autosomal recessive muscular dystrophy muscle. Biochem Biophys Res Commun 1994;203:979-983
    CrossRef | Web of Science | Medline

  24. 24

    Sewry CA, Samsome A, Matsumura K, Campbell KP, Dubowitz V. Deficiency of the 50 kDa dystrophin-associated glycoprotein and abnormal expression of utrophin in two south Asian cousins with variable expression of severe childhood autosomal recessive muscular dystrophy. Neuromuscul Disord 1994;4:121-129
    CrossRef | Web of Science | Medline

  25. 25

    McNally EM, Selig S, Kunkel LM. Adhalin, the 50 kD dystrophin associated protein, is not the locus for severe childhood autosomal recessive dystrophy (SCARMD). Am J Hum Genet 1994;55:Suppl:A135-A135 abstract.

  26. 26

    Roberds SL, Leturcq F, Allamand V, et al. Missense mutations in the adhalin gene linked to autosomal recessive muscular dystrophy. Cell 1994;78:625-633
    CrossRef | Web of Science | Medline

  27. 27

    Piccolo F, Roberds SL, Jeanpierre M, et al. Primary adhalinopathy: a common cause of autosomal recessive muscular dystrophy of variable severity. Nat Genet 1995;10:243-245
    CrossRef | Web of Science | Medline

  28. 28

    Ervasti JM, Ohlendieck K, Kahl SD, Gaver MG, Campbell KP. Deficiency of a glycoprotein component of the dystrophin complex in dystrophic muscle. Nature 1990;345:315-319
    CrossRef | Web of Science | Medline

  29. 29

    Ohlendieck K, Campbell KP. Dystrophin-associated proteins are greatly reduced in skeletal muscle from mdx mice. J Cell Biol 1991;115:1685-1694
    CrossRef | Web of Science | Medline

  30. 30

    Engel AG. The muscle biopsy. In: Engel AG, Franzini-Armstrong C, eds. Myology. New York: McGraw-Hill, 1994:822-9.

  31. 31

    Roberds SL, Ervasti JM, Anderson RD, et al. Disruption of the dystrophin-glycoprotein complex in the cardiomyopathic hamster. J Biol Chem 1993;268:11496-11499
    Web of Science | Medline

  32. 32

    Palmucci L, Doriguzzi C, Mongini T, et al. Dilating cardiomyopathy as the expression of Xp21 Becker type muscular dystrophy. J Neurol Sci 1992;111:218-221
    CrossRef | Web of Science | Medline

  33. 33

    Nonaka I, Sugita H, Takada K, Kumagai K. Muscle histochemistry in congenital muscular dystrophy with central nervous system involvement. Muscle Nerve 1982;5:102-106
    CrossRef | Web of Science | Medline

  34. 34

    Kuhn E, Fiehn W, Schroder JM, Assmus H, Wagner A. Early myocardial disease and cramping myalgia in Becker-type muscular dystrophy: a kindred. Neurology 1979;29:1144-1149
    Web of Science | Medline

  35. 35

    Borgeat A, Gay JJ, Sigwart U. Acute pulmonary edema as the inaugural symptom of Becker's muscular dystrophy in a 19-year-old patient. Clin Cardiol 1987;10:127-129
    CrossRef | Web of Science | Medline

  36. 36

    Casazza F, Brambilla G, Salvato A, Morandi L, Gronda E, Bonacina E. Cardiac transplantation in Becker muscular dystrophy. J Neurol 1988;235:496-498
    CrossRef | Web of Science | Medline

  37. 37

    Donofrio PD, Challa VR, Hackshaw BT, Mills SA, Cordell AR. Cardiac transplantation in a patient with muscular dystrophy and cardiomyopathy. Arch Neurol 1989;46:705-707
    Web of Science | Medline

  38. 38

    Towbin JA, Hejtmancik JF, Brink P, et al. X-linked dilated cardiomyopathy: molecular genetic evidence of linkage to the Duchenne muscular dystrophy (dystrophin) gene at the Xp21 locus. Circulation 1993;87:1854-1865
    Web of Science | Medline

  39. 39

    Muntoni F, Cau M, Ganau A, et al. Deletion of the dystrophin muscle-promoter region associated with X-linked dilated cardiomyopathy. N Engl J Med 1993;329:921-925
    Full Text | Web of Science | Medline

  40. 40

    Yoshida K, Ikeda S, Nakamura A, et al. Molecular analysis of the Duchenne muscular dystrophy gene in patients with Becker muscular dystrophy presenting with dilated cardiomyopathy. Muscle Nerve 1993;16:1161-1166
    CrossRef | Web of Science | Medline

  41. 41

    Michels VV, Pastores GM, Moll PP, et al. Dystrophin analysis in idiopathic dilated cardiomyopathy. J Med Genet 1993;30:955-957
    CrossRef | Web of Science | Medline

Citing Articles (23)

Citing Articles

  1. 1

    Tomie Kawada, Fujiko Masui, Asaki Tezuka, Takashi Ebisawa, Hiroyuki Kumagai, Mikio Nakazawa, Teruhiko Toyo-oka. (2005) A novel scheme of dystrophin disruption for the progression of advanced heart failure. Biochimica et Biophysica Acta (BBA) - Proteins & Proteomics 1751:1, 73-81
    CrossRef

  2. 2

    Tomie Kawada, Fujiko Masui, Hiroyuki Kumagai, Miki Koshimizu, Mikio Nakazawa, Teruhiko Toyo-oka. (2005) A novel paradigm for therapeutic basis of advanced heart failure—assessment by gene therapy. Pharmacology & Therapeutics 107:1, 31-43
    CrossRef

  3. 3

    Weixing Shi, Zaili Chen, Jodi Schottenfeld, Richard C. Stahl, Louis M. Kunkel, Yiu-Mo Chan. (2004) Specific assembly pathway of sarcoglycans is dependent on beta- and delta-sarcoglycan. Muscle & Nerve 29:3, 409-419
    CrossRef

  4. 4

    Tomie KAWADA, Mikio NAKAZAWA, Teruhiko TOYO-OKA. (2004) A new paradigm for the progression of advanced heart failure.. Folia Pharmacologica Japonica 123:2, 55-62
    CrossRef

  5. 5

    S ISOBE, A ANDO, M NANASATO, M NONOKAWA, H IZAWA, T SOBUE, M HIRAI, K ITO, T ISHIGAKI, T MUROHARA, M YOKOTA. (2003) Combined study with FDG PET and Tl SPECT in patients with idiopathic dilated cardiomyopathy. Nuclear Medicine Communications 24:10, 1071-1080
    CrossRef

  6. 6

    M. Fanin, P. Melacini, C. Boito, E. Pegoraro, C. Angelini. (2003) LGMD2E patients risk developing dilated cardiomyopathy. Neuromuscular Disorders 13:4, 303-309
    CrossRef

  7. 7

    Jeffrey A Towbin, Neil E Bowles. (2002) Molecular diagnosis of myocardial disease. Expert Review of Molecular Diagnostics 2:6, 587-602
    CrossRef

  8. 8

    Niall G Mahon, Brendan P Madden, Alida L.P Caforio, Perry M Elliott, Aldwyn J Haven, Bruce E Keogh, Michael J Davies, William J McKenna. (2002) Immunohistologic evidence of myocardial disease in apparently healthy relatives of patients with dilated cardiomyopathy. Journal of the American College of Cardiology 39:3, 455-462
    CrossRef

  9. 9

    Slobodanka Djukic, Maja Vivoda, Biljana Arsic, Eliana Garalejic, Natasa Opavski, Vera Mijac, Lazar Ranin. (2002) Da li je vanmaterična trudnoća moguća komplikacija hlamidijske infekcije?. Srpski arhiv za celokupno lekarstvo 130:11-12, 420-424
    CrossRef

  10. 10

    L Politano, V Nigro, L Passamano, V Petretta, L.I Comi, S Papparella, Ge Nigro, P.F Rambaldi, P Raia, A Pini, M Mora, M.A.M Giugliano, M.G Esposito, G Nigro. (2001) Evaluation of cardiac and respiratory involvement in sarcoglycanopathies. Neuromuscular Disorders 11:2, 178-185
    CrossRef

  11. 11

    Alan W Spier, Kathryn M. Meurs, Daniel D Coovert, Linda B. Lehmkuhl, Michael R. O'Grady, Lisa M. Freeman, Arthur H. Burghes, Jeffrey A. Towbin. (2001) Use of western immunoblot for evaluation of myocardial dystrophin, -sarcoglycan, and -dystroglycan in dogs with idiopathic dilated cardiomyopathy. American Journal of Veterinary Research 62:1, 67-71
    CrossRef

  12. 12

    Kathryn M. Meurs, Alex L. Magnon, Alan W. Spier, Mathew W. Miller, Linda B. Lehmkuhl, Jeffrey A. Towbin. (2001) Evaluation of the cardiac actin gene in Doberman Pinschers with dilated cardiomyopathy. American Journal of Veterinary Research 62:1, 33-36
    CrossRef

  13. 13

    W. Robert Morrow. (2000) Cardiomyopathy and heart transplantation in children. Current Opinion in Cardiology 15:4, 216-223
    CrossRef

  14. 14

    Wolfgang-Michael Franz, Matthias Muller, Oliver J Muller, Ralf Herrmann, Thomas Rothmann, Marion Cremer, Ronald D Cohn, Thomas Voit, Hugo A Katus. (2000) Association of nonsense mutation of dystrophin gene with disruption of sarcoglycan complex in X-linked dilated cardiomyopathy. The Lancet 355:9217, 1781-1785
    CrossRef

  15. 15

    Andrew A. Hack, Margaret E. Groh, Elizabeth M. McNally. (2000) Sarcoglycans in muscular dystrophy. Microscopy Research and Technique 48:3-4, 167-180
    CrossRef

  16. 16

    Tomaso Gnecchi-Ruscone, Jackie Taylor, Eugenio Mercuri, Giovanni Paternostro, Robert Pogue, Kate Bushby, Caroline Sewry, Francesco Muntoni, Paolo G. Camici. (1999) Cardiomyopathy in Duchenne, Becker, and sarcoglycanopathies: A role for coronary dysfunction?. Muscle & Nerve 22:11, 1549-1556
    CrossRef

  17. 17

    Luisa Mestroni, Chiara Rocco, Dario Gregori, Gianfranco Sinagra, Andrea Di Lenarda, Snjezana Miocic, Matteo Vatta, Bruno Pinamonti, Francesco Muntoni, Alida L.P. Caforio, William J. McKenna, Arturo Falaschi, Mauro Giacca, Fulvio Camerini. (1999) Familial dilated cardiomyopathy. Journal of the American College of Cardiology 34:1, 181-190
    CrossRef

  18. 18

    P. Melacini, M. Fanin, D.J. Duggan, M.P. Freda, A. Berardinelli, G.A. Danieli, A. Barchitta, E.P. Hoffman, S. Dalla Volta, C. Angelini. (1999) Heart involvement in muscular dystrophies due to sarcoglycan gene mutations. Muscle & Nerve 22:4, 473-479
    CrossRef

  19. 19

    Leland E. Lim, Kevin P. Campbell. (1998) The sarcoglycan complex in limb–girdle muscular dystrophy. Current Opinion in Neurology 11:5, 443-452
    CrossRef

  20. 20

    Eijiro Ozawa, Satoru Noguchi, Yuji Mizuno, Yasuko Hagiwara, Mikiharu Yoshida. (1998) From dystrophinopathy to sarcoglycanopathy: Evolution of a concept of muscular dystrophy. Muscle & Nerve 21:4, 421-438
    CrossRef

  21. 21

    Jeffrey A Towbin. (1998) The role of cytoskeletal proteins in cardiomyopathies. Current Opinion in Cell Biology 10:1, 131-139
    CrossRef

  22. 22

    MAAP Willemsen, AM Oort, HJ Laak, RCA Sengers, FJM Gabreëls. (1997) Multicore myopathy with restrictive cardiomyopathy. Acta Paediatrica 86:11, 1271-1274
    CrossRef

  23. 23

    (1996) Deficiency of Adhalin in a Patient with Muscular Dystrophy and Cardiomyopathy. New England Journal of Medicine 334:24, 1610-1611
    Full Text

Letters